NeuroAiD

NeuroAiD is an oral treatment used to support functional recovery after strokes.[1] It has also shown effectiveness as a complementary treatment for other brain injuries and Alzheimer's disease.[2] There were two formulations of NeuroAiD: MLC601 (NeuroAiDTM) was first developed.[1] Since 2018 MLC601 formulation is no longer on the market, and has been replaced by MLC901 (NeuroAiDTMII), a simplified formulation containing only 9 botanical ingredients.[3] It can be administered orally or through a feeding tube.[2]

Common side effects include abdominal discomfort, headaches, dry mouth, nausea, vomiting, and diarrhea.[1] Though very rare, some patients have reported serious adverse events in clinical trials (jaundice, hypokalemia, seizures, and recurring strokes), none being related to treatment according to investigators' opinion.[4]

NeuroAiD was first registered and marketed in China in 2001.[1][5] It was patented in the United States in 2013,[6] but has not yet been approved by the FDA. NeuroAiD is distributed by Moleac,[7] and is derived from traditional Chinese medicine.[5][4][8] According to the CEO of Moleac, NeuroAiD is sold in at least 25 countries, and 20,000 people have taken it.[9]

Composition

NeuroAid I, or MLC601, is composed of nine herbal components (astragalus root, Salvia miltiorrhiza root, chishao, rhizome lovage, Angelica sinensis root, safflower, peach, thinleaf milkwort root, and grassleaf sweet flag rhizome) and five components derived from animals (Hirudo medicinalis, Eupolyphaga seu steleophaga, Calculus bovis artifactus, Buthus martensii, and Cornu saigae tataricae).[10] NeuroAiDTMII, or MLC901, is a simpler form of the medication that only contains the nine herbal components without the animal components.[3] Since 2018, MLC601 formulation is no longer marketed.

Approvals and patents

NeuroAiD was approved by the Sino Food and Drug Administration in August 2001, under the name Danqi Piantan Jiaonang.[10][11] NeuroAiD has also been approved for use in other Asian countries such as Singapore.[12] In 2006, NeuroAiD was also chosen for the Chinese Ministry of Science and Technology's Key Technologies Research & Development program.[13]

In 2013, Moleac filed a patent for NeuroAiD with the European Patent Office, which was eventually approved in 2019.[14] In the same year, Moleac also filed a patent application with the U.S. Patent Office.[6]

References
  1. Venketasubramanian N, Kumar R, Soertidewi L, Abu Bakar A, Laik C, Gan R (November 2015). "The NeuroAiD Safe Treatment (NeST) Registry: a protocol". BMJ Open. 5 (11): e009866. doi:10.1136/bmjopen-2015-009866. PMC 4654343. PMID 26567259.
  2. Chen CL, Sharma PR, Tan BY, Low C, Venketasubramanian N (2019). "The Alzheimer's disease THErapy with NEuroaid (ATHENE) study protocol: Assessing the safety and efficacy of Neuroaid II (MLC901) in patients with mild-to-moderate Alzheimer's disease stable on cholinesterase inhibitors or memantine-A randomized, double-blind, placebo-controlled trial". Alzheimer's & Dementia. 5: 38–45. doi:10.1016/j.trci.2018.12.001. PMC 6352850. PMID 30723778.
  3. Heurteaux C, Gandin C, Borsotto M, Widmann C, Brau F, Lhuillier M, Onteniente B, Lazdunski M (June 2010). "Neuroprotective and neuroproliferative activities of NeuroAid (MLC601, MLC901), a Chinese medicine, in vitro and in vivo". Neuropharmacology. 58 (7): 987–1001. doi:10.1016/j.neuropharm.2010.01.001. PMID 20064536.
  4. Siddiqui FJ, Venketasubramanian N, Chan ES, Chen C (2013). "Efficacy and safety of MLC601 (NeuroAiD), a traditional Chinese medicine, in poststroke recovery: a systematic review". Cerebrovasc Dis. 35 Suppl 1: 8–17. doi:10.1159/000346231. PMID 23548914.
  5. Tan CN, Choy D, Venketasubramanian N (2020). "NeuroAid II (MLC901) in Haemorrhagic Stroke". Case Rep Neurol. 12 (Suppl 1): 212–217. doi:10.1159/000508588. PMC 7802497. PMID 33505298.
  6. Novel uses for traditional Chinese medicines.
  7. Heurteaux C, Widmann C, Moha ou Maati H, Quintard H, Gandin C, Borsotto M, Veyssiere J, Onteniente B, Lazdunski M (2013). "NeuroAiD: properties for neuroprotection and neurorepair". Cerebrovasc Dis. 35 Suppl 1: 1–7. doi:10.1159/000346228. PMID 23548913.
  8. Widmann C, Gandin C, Petit-Paitel A, Lazdunski M, Heurteaux C (December 2018). "The Traditional Chinese Medicine MLC901 inhibits inflammation processes after focal cerebral ischemia". Sci Rep. 8 (1): 18062. doi:10.1038/s41598-018-36138-0. PMC 6305383. PMID 30584250.
  9. "Herbal stroke remedy no better than dummy pill". Reuters. 2013-07-05.
  10. Kim I, Pollitt E, Leibel RL, Viteri FE, Alvarez E (September 1984). "Application of receiver-operator analysis to diagnostic tests of iron deficiency in man". Pediatr Res. 18 (9): 916–20. doi:10.1203/00006450-198409000-00025. PMID 6483514.
  11. Gan R, Lambert C, Lianting J, Chan ES, Venketasubramanian N, Chen C, Chan BP, Samama MM, Bousser MG (2008). "Danqi Piantan Jiaonang does not modify hemostasis, hematology, and biochemistry in normal subjects and stroke patients". Cerebrovasc Dis. 25 (5): 450–6. doi:10.1159/000126919. PMID 18417963.
  12. Siow CH (2008). "Neuroaid in stroke recovery". Eur Neurol. 60 (5): 264–6. doi:10.1159/000155220. PMID 18781074.
  13. Chen C, Venketasubramanian N, Gan RN, Lambert C, Picard D, Chan BP, Chan E, Bousser MG, Xuemin S (March 2009). "Danqi Piantang Jiaonang (DJ), a traditional Chinese medicine, in poststroke recovery". Stroke. 40 (3): 859–63. doi:10.1161/STROKEAHA.108.531616. PMID 19164787.
  14. EP2838545A1 - European Patent Office
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.